Response to the second round review inquiry letter of Zhejiang Shengda Biopharmaceutical Co., Ltd. to issue stock application documents to specific targets (revised draft) (2023 financial data update)

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.